^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LMP744

    i
    Other names: LMP744, LMP 744, NSC 706744, NSC706744, MJ-III-65, LMP-744
    Associations

    News

    Trials
    Company:
    Gibson Oncology, National Cancer Institute, Purdue University
    Drug class:
    Topoisomerase I inhibitor, MYC inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas. (PubMed, Cancer Chemother Pharmacol)
    MTDs and safety profiles are reported for LMP776 and LMP744. Target engagement by an indenoisoquinoline was measured for the first time in human samples.
    P1 data • Journal
    |
    SLFN11 (Schlafen Family Member 11) • RAD51 (RAD51 Homolog A) • CASP3 (Caspase 3)
    |
    LMP744 • indotecan (LMP400)
    2years
    Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1, N=36, Completed, National Cancer Institute (NCI) | Recruiting --> Completed | N=53 --> 36
    Trial completion • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    LMP744
    over3years
    Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1, N=53, Recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    LMP744